News

News | May 07, 2019

At the Bloom Burton & Co. Healthcare Investor Conference in Toronto, which took place from April 30 to May 1, experts in the industry sat down for a panel discussion called “Investing in Commercial Stage Healthcare Companies.” They focused largely on drug price issues in the US, political implications for the industry and the struggles

Press Release | May 02, 2019

Misonix, Inc. (Nasdaq: MSON) (“Misonix”) a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced today that it has entered into a definitive agreement with Solsys Medical, LLC (“Solsys”), a privately held regenerative medical company, to acquire Solsys in an all-stock transaction valued at approximately $97 million. Under the terms of

News | Apr 08, 2019

Oliva will be honored with the 2019 Hall of Fame Award from SJU’s Haub School of Business on April 9, 2019 at The Union League of Philadelphia. A proud SJU grad, Oliva has been a healthcare investor for over 20 years and focuses on commercial stage medical technology, healthcare service, and specialty pharmaceutical investments. You

Press Release | Apr 08, 2019

Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and cleantech industries, announced today it has provided a $20 million venture loan facility to Encore Dermatology, Inc. (“Encore”), of

Press Release | Apr 02, 2019

Encore Dermatology Inc. announced today that it has acquired rights for SERNIVO® (betamethasone dipropionate) Spray, 0.05%, as well as rights to market and distribute TRIANEX® 0.05% (Triamcinolone Acetonide Ointment, USP) and PROMISEB® Topical Cream in the United States from Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), through its wholly owned subsidiary Promius

Press Release | Apr 02, 2019

Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), through its wholly owned subsidiary Promius Pharma, LLC, announces the sale of its rights for SERNIVO® (betamethasone dipropionate) Spray, 0.05% and assignment of its rights to market and distribute, PROMISEB® Topical Cream and TRIANEX® 0.05%

Pages 1 2 3 4 5 6 7 11